The authors demonstrated that AGD1, derived from prostate cancer stem cells, enhanced the stemness of prostate cancer cells and reduced the therapeutic effect of docetaxel in castration-resistant prostate cancer.
[Journal of Experimental & Clinical Cancer Research]